Impact of medication reviews on potentially inappropriate medications and associated costs among older women in aged care
Copyright © 2022 Elsevier Inc. All rights reserved..
BACKGROUND: The Residential Medication Management Review (RMMR) service is a large investment by the Australian government and involves considerable time commitment.
OBJECTIVES: This study determined the impact of RMMRs on the use of potentially inappropriate medications (PIMs), benzodiazepines and antidepressants, described patterns of PIM use, and examined costs.
METHODS: The study included 5576 participants from the Australian Longitudinal Study on Women's Health from 2005 to 2017. Three generalised estimating equation (GEE) models were specified to separately analyse the impact of RMMRs on the use of PIMs, benzodiazepines and antidepressants. Descriptive statistics were used to present, at each year, the proportions of participants with PIMs, patterns of PIMs and costs of PIMs.
RESULTS: There was no evidence for an association between the use of RMMRs and the use of PIMs (OR = 0.99; 95% CI = 0.88, 1.11), benzodiazepines (OR = 1.02; 95% CI = 0.95, 1.08) or antidepressants (OR = 0.99; 95% CI = 0.90, 1.10) in the following year. There were few differences in the use of particular classes of PIMs, nor any differences in the median benefits paid by government or out-of-pocket costs, between participants who did and did not receive RMMRs. There was a slight increase in median OOP costs and a decrease in government benefits over time.
CONCLUSIONS: There was a lack of long-term changes on use of PIMs, however, its appropriate use must be considered during RMMRs. Healthcare professionals have an obligation to optimise the service to reduce medication costs whilst improving health outcomes among individuals residing in RACF.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:18 |
|---|---|
| Enthalten in: |
Research in social & administrative pharmacy : RSAP - 18(2022), 10 vom: 13. Okt., Seite 3758-3765 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Thiruchelvam, Kaeshaelya [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
12794-10-4 |
|---|
| Anmerkungen: |
Date Completed 23.08.2022 Date Revised 29.09.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.sapharm.2022.05.003 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM341005754 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM341005754 | ||
| 003 | DE-627 | ||
| 005 | 20231226010754.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.sapharm.2022.05.003 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1136.xml |
| 035 | |a (DE-627)NLM341005754 | ||
| 035 | |a (NLM)35577744 | ||
| 035 | |a (PII)S1551-7411(22)00153-X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Thiruchelvam, Kaeshaelya |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Impact of medication reviews on potentially inappropriate medications and associated costs among older women in aged care |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.08.2022 | ||
| 500 | |a Date Revised 29.09.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 Elsevier Inc. All rights reserved. | ||
| 520 | |a BACKGROUND: The Residential Medication Management Review (RMMR) service is a large investment by the Australian government and involves considerable time commitment | ||
| 520 | |a OBJECTIVES: This study determined the impact of RMMRs on the use of potentially inappropriate medications (PIMs), benzodiazepines and antidepressants, described patterns of PIM use, and examined costs | ||
| 520 | |a METHODS: The study included 5576 participants from the Australian Longitudinal Study on Women's Health from 2005 to 2017. Three generalised estimating equation (GEE) models were specified to separately analyse the impact of RMMRs on the use of PIMs, benzodiazepines and antidepressants. Descriptive statistics were used to present, at each year, the proportions of participants with PIMs, patterns of PIMs and costs of PIMs | ||
| 520 | |a RESULTS: There was no evidence for an association between the use of RMMRs and the use of PIMs (OR = 0.99; 95% CI = 0.88, 1.11), benzodiazepines (OR = 1.02; 95% CI = 0.95, 1.08) or antidepressants (OR = 0.99; 95% CI = 0.90, 1.10) in the following year. There were few differences in the use of particular classes of PIMs, nor any differences in the median benefits paid by government or out-of-pocket costs, between participants who did and did not receive RMMRs. There was a slight increase in median OOP costs and a decrease in government benefits over time | ||
| 520 | |a CONCLUSIONS: There was a lack of long-term changes on use of PIMs, however, its appropriate use must be considered during RMMRs. Healthcare professionals have an obligation to optimise the service to reduce medication costs whilst improving health outcomes among individuals residing in RACF | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Aged care | |
| 650 | 4 | |a Costs | |
| 650 | 4 | |a Medication review | |
| 650 | 4 | |a Potentially inappropriate medications | |
| 650 | 4 | |a Residential medication management review | |
| 650 | 7 | |a Benzodiazepines |2 NLM | |
| 650 | 7 | |a 12794-10-4 |2 NLM | |
| 700 | 1 | |a Byles, Julie |e verfasserin |4 aut | |
| 700 | 1 | |a Hasan, Syed Shahzad |e verfasserin |4 aut | |
| 700 | 1 | |a Egan, Nicholas |e verfasserin |4 aut | |
| 700 | 1 | |a Kairuz, Therese |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Research in social & administrative pharmacy : RSAP |d 2005 |g 18(2022), 10 vom: 13. Okt., Seite 3758-3765 |w (DE-627)NLM166902047 |x 1934-8150 |7 nnns |
| 773 | 1 | 8 | |g volume:18 |g year:2022 |g number:10 |g day:13 |g month:10 |g pages:3758-3765 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.sapharm.2022.05.003 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 18 |j 2022 |e 10 |b 13 |c 10 |h 3758-3765 | ||